Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_assertion type Assertion NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_head.
- NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_assertion description "[Inhibition of MAPK activity with MAP kinase kinase (MEK) inhibitor PD98059 blocks early stages of cell migration (up to 4 h); however, cells revert back to enhanced cell migration after 4 h. While inhibition of PKC-delta activity with rottlerin or dominant-negative PKC-delta expression blocks sustained cell migration after 4 h and up to 12 h, the combination of MAPK and PKC inhibitors completely blocked transforming growth factor alpha (TGF-alpha)-induced cell migration in EGFR-overexpressing breast cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_provenance.
- NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_assertion evidence source_evidence_literature NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_provenance.
- NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_assertion SIO_000772 14517342 NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_provenance.
- NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_assertion wasDerivedFrom befree-2016 NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_provenance.
- NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_assertion wasGeneratedBy ECO_0000203 NP415058.RA6o6OIgOkEAAqScNjrUDcZQiH7ypmUSkfHkdnvwo8i1w130_provenance.